Caption Management 13F: New $5.5M Stake in ADMA Biologics (ADMA)

Caption Management Establishes New Stake in ADMA Biologics

Caption Management opened a new position in ADMA Biologics, Inc. (NasdaqGM: ADMA), purchasing 660,000 shares during the period. The newly initiated stake carries a reported value of about $5.54 million based on the filing data. Institutional 13F filings are backward-looking and reflect holdings as of the end of the reporting period, meaning this position may not represent the fund's current holdings today.

ADMA Biologics Stock Performance and Valuation

Shares of ADMA Biologics recently traded around $8.39, sitting between its 52-week low of $7.21 and high of $20.46. The company carries a market capitalization of roughly $2.13 billion and a P/E ratio of 13.58, alongside a forward P/E ratio of 10.08. Its 50-day moving average rests at $9.20, while the 200-day moving average stands at $12.20.

Analysts Set New Price Targets

Analyst coverage includes a recent update from Mizuho. On July 15, 2026, Mizuho maintained its Outperform rating on ADMA Biologics while adjusting its price target to $17.00 from $20.00. Across four analysts covering the firm, the consensus recommendation stands at buy, with a mean price target of $17.00.

Inside ADMA Biologics Operations

ADMA Biologics, Inc. is a biopharmaceutical company based in Ramsey, New Jersey. The company focuses on developing, manufacturing, and marketing specialty plasma-derived biologics. These products target immune deficiencies and infectious diseases across domestic and international markets through its bio-manufacturing and plasma collection segments.

Looking Ahead at Filings and Earnings

Investors tracking Caption Management will need to wait for subsequent quarterly disclosures to see whether the fund adjusts this share count. Meanwhile, ADMA Biologics is scheduled to release its next round of earnings reports on November 4, 2026.